Cambridge Trust Co. Purchases New Position in Revvity, Inc. (NYSE:RVTY)

Cambridge Trust Co. purchased a new position in Revvity, Inc. (NYSE:RVTY) in the fourth quarter, Holdings Channel reports. The institutional investor purchased 1,233 shares of the company’s stock, valued at approximately $135,000.

Several other hedge funds also recently made changes to their positions in RVTY. KBC Group NV purchased a new position in Revvity during the third quarter valued at approximately $25,301,000. Public Sector Pension Investment Board purchased a new position in Revvity during the third quarter worth about $1,472,000. 2Xideas AG purchased a new position in Revvity during the third quarter worth about $20,968,000. Citigroup Inc. bought a new position in Revvity in the 3rd quarter worth about $5,548,000. Finally, Wesbanco Bank Inc. purchased a new stake in shares of Revvity in the 3rd quarter valued at about $522,000. 86.65% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Revvity

In other Revvity news, insider Prahlad R. Singh sold 21,217 shares of Revvity stock in a transaction on Monday, February 5th. The stock was sold at an average price of $104.28, for a total value of $2,212,508.76. Following the completion of the sale, the insider now owns 92,801 shares of the company’s stock, valued at approximately $9,677,288.28. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.60% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research analysts have recently commented on RVTY shares. Barclays boosted their price objective on Revvity from $92.00 to $105.00 and gave the stock an “equal weight” rating in a report on Thursday, January 25th. Stifel Nicolaus increased their price target on shares of Revvity from $95.00 to $110.00 and gave the stock a “hold” rating in a report on Friday, February 2nd. Evercore ISI upgraded shares of Revvity from an “in-line” rating to an “outperform” rating and raised their price objective for the company from $88.00 to $125.00 in a research report on Thursday, January 4th. UBS Group lowered shares of Revvity from a “buy” rating to a “neutral” rating and upped their target price for the stock from $105.00 to $125.00 in a research report on Tuesday, January 16th. Finally, Raymond James raised their price target on Revvity from $106.00 to $127.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $118.91.

Revvity Trading Up 1.5 %

NYSE:RVTY opened at $100.86 on Friday. Revvity, Inc. has a one year low of $79.50 and a one year high of $135.67. The company’s 50-day simple moving average is $104.78 and its 200 day simple moving average is $101.64. The firm has a market capitalization of $12.46 billion, a P/E ratio of 18.34, a PEG ratio of 2.59 and a beta of 1.09. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.07 and a quick ratio of 1.77.

Revvity (NYSE:RVTY) last posted its quarterly earnings data on Thursday, February 1st. The company reported $1.25 earnings per share for the quarter, beating analysts’ consensus estimates of $1.15 by $0.10. Revvity had a return on equity of 7.41% and a net margin of 25.20%. The company had revenue of $695.90 million during the quarter. As a group, analysts forecast that Revvity, Inc. will post 4.65 EPS for the current fiscal year.

Revvity Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 10th. Investors of record on Friday, April 19th will be given a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.28%. The ex-dividend date of this dividend is Thursday, April 18th. Revvity’s dividend payout ratio (DPR) is 5.09%.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.